Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement system on the attack in autoimmunity.

John P Atkinson1

  • 1Washington University School of Medicine, St. Louis, Missouri 63110-1093, USA. jatkinso@im.wustl.edu

The Journal of Clinical Investigation
|December 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of missense variants in the signal peptide of C1 esterase inhibitor.

The Journal of allergy and clinical immunology·2026
Same author

Adipose-driven complement-lipid reprogramming controls nociceptive vulnerability in obesity-associated osteoarthritis.

bioRxiv : the preprint server for biology·2026
Same author

Complement system in cancer: friend or foe of immunotherapy.

Journal for immunotherapy of cancer·2026
Same author

Neuroimaging Biomarkers of Disease Progression and Cognitive Change in Patients With Retinal Vasculopathy With Cerebral Leukoencephalopathy.

Neurology·2026
Same author

Activation of the alternative complement pathway and its relevance for sodium retention in experimental nephrotic syndrome.

Pflugers Archiv : European journal of physiology·2026
Same author

Longitudinal association of retinal morphology and white matter progression in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations.

Frontiers in neurology·2025
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
Same journal

Ammonia in the crosshairs: microbial targets for metabolic dysfunction-associated steatohepatitis prevention.

The Journal of clinical investigation·2026
Same journal

Molecular mechanisms regulating cGAS/STING activation in health and disease.

The Journal of clinical investigation·2026
See all related articles

Antiphospholipid syndrome causes fetal loss and thrombosis. Blocking complement activation, specifically complement component 5a (C5a), prevented these in a mouse model, suggesting a potential therapy.

Area of Science:

  • Immunology
  • Obstetrics
  • Hematology

Background:

  • Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by recurrent thrombosis and pregnancy complications like fetal loss.
  • Serologically, APS is defined by the presence of autoantibodies against lipid-binding proteins.

Discussion:

  • This study investigated the role of the complement system in a mouse model of APS.
  • Complement activation, particularly the interaction of complement component 5a (C5a) with its receptor, was found to be crucial for the development of placental vascular thrombosis.

Key Insights:

  • Blocking complement activation effectively prevented fetal loss in a mouse model of APS.
  • Inhibition of the C5a-receptor pathway is a potential therapeutic strategy for APS-related complications.

Related Experiment Videos

Outlook:

  • Further research into complement inhibitors could lead to novel treatments for antiphospholipid syndrome.
  • Targeting complement activation pathways may offer a way to manage both thrombotic and obstetric manifestations of APS.